

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :  
Shanler et al. : Confirmation No.: 4999  
Serial No. 10/763,807 : Group Art Unit: 1617  
Filed: January 22, 2004 : Examiner: Cotton, Abigail Manda  
For: METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS  
FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-  
ADRENORECEPTOR AGONISTS

**RESPONSE TO RESTRICTION REQUIREMENT**

Amendment  
Commissioner for Patents  
Washington, D.C. 20231

Dear Madam:

This is a response to the restriction requirement mailed in the Office Action dated June 20, 2007 in the above identified application. Applicant elects, with traverse, the invention that the Examiner has designated as Invention I (Claims 1-11 and 13-16) directed to a method for treating at least one condition selected from the group consisting of rosacea, acne, skin redness or other discrete erythema of the skin by administering topically at least one  $\alpha_1$  adrenoreceptor agonist and further elects, with traverse, oxymetazoline as the  $\alpha_1$  adrenoreceptor agonist and rosacea as the condition.

The Office Action set forth a one-month shortened statutory period for reply. Accordingly, this response is timely filed and is fully responsive to the Office Action.

**Claims** begin on page 2.

**Remarks** being on page 5.